In mouse models, imatinib reduced the expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), leading to increased CD8+ T-cells in the tumor [33] and thereby an increased chance of CD8+ T-cell attack of tumor cells. Here, IDO2 is linked to neoplasm.